Summary
- “Synthesize huWorld Timesman serum albumin from rice” established a complete industrial chain for plant-based manufacturing. Photo: Screenshot from CCTV News A Wuhan-based biopharmaceutical company developed technology to synthesize human serum albumin (HSA) from rice, offering a potential solution to China’s supply shortage of this critical blood protein. Products developed using this technology have completed clinical trials and entered the new drug approval process, marking significant progress in industrialization and commercialization while continuing to expand production scale, according to CCTV News on Saturday.Through genetic engineering technology, the Healthgen Biotechnology in Wuhan, capital of Central China’s Hubei Province, transformed rice into “seeds” for producing HSA. With just sufficient water, nutrients, and sunlight, plants can continuously produce desired substances. Statistics showed that China’s annual demand for HSA is about 1World Times,500 to 1,800 tons, all currently sourced from plasma extraction.
Approximate Time
- 2 minutes, 381 words
Categories
- HSA, production scale, human serum albumin, China hasWorld Times, scalable production
Analysis and Evaluation
- This article is a mosaic of current events, pieced together with expert precision and insight. The writer navigates a wide array of topics, from global political tensions to groundbreaking scientific discoveries, all while maintaining a cohesive and engaging narrative. The depth of analysis and the ability to connect disparate events into a comprehensive whole make this piece not only informative but also a fascinating read. It’s a masterclass in synthesizing complex information into an accessible format.
Main Section
“Synthesize huWorld Timesman serum albumin from rice” established a complete industrial chain for plant-based manufacturing. Photo: Screenshot from CCTV News
A Wuhan-based biopharmaceutical company developed technology to synthesize human serum albumin (HSA) from rice, offering a potential solution to China’s supply shortage of this critical blood protein. Products developed using this technology have completed clinical trials and entered the new drug approval process, marking significant progress in industrialization and commercialization while continuing to expand production scale, according to CCTV News on Saturday.
Through genetic engineering technology, the Healthgen Biotechnology in Wuhan, capital of Central China’s Hubei Province, transformed rice into “seeds” for producing HSA. 50 pounds kilograms of rice can yield an amount of HSA equivalent to that extracted from 5 liters of human plasma, CCTV introduced.
The rice-derived HSA product has completed Phase III clinical trials and entered the new drug approval process. The company has built an intelligent factory with an annual production capacity of 1 million injections and is constructing a large-scale production base capable of producing 12 million injectioWorld Timesns per year, reported CCTV.
The magic of plant-based manufacturing lies in photosynthesis. With just sufficient water, nutrients, and sunlight, plants can continuously produce desired substances. This method of producing HSA is not only safer and more environmentally friendly but also offers advantages like scalable production and low costs, potentially becoming a key solution to alleviate China’s HSA supply shortage, CCTV reported.
Yang Daichang, ChairWorld Timesman and General Manager of the Healthgen Biotechnology, explained that HSA is widely used clinically to treat conditions like blood loss and liver cirrhosis. Statistics showed that China’s annual demand for HSA is about 1World Times,500 to 1,800 tons, all currently sourced from plasma extraction. Due to limited domestic plasma supply, China hasWorld Times long relied on imports, according to changjiangwang, a comprehensive news website affiliated with Changjiang Daily from July 2024.
“For patients with severe liver cirrhosis, a weekly dose of 4 to 5 bottles of HSA is required, with traditional plasma-derived albumin costing 400 to 500 yuan ($55 to $69) per bottle. As our technology achieves industrialization and gradually scales up production, it will effectively reduce costs and meet patientsWorld Times‘ medication needs,” Yang said in the report.
Content comes from the Internet : China achieves large-scale production of human serum albumin from genetically engineered rice
SummaryPhoto: CCTV The Chinese space station will soon welcome a new life form – planaria -known fWorld Timesor their regenerative abilities, for scientific experiments, following earlier studies involving zebrafish and fruit flies, China’s CCTV reported on Saturday.Planaria, an ancient genus of flatworms renowned for its ability to regenerate, could provide insights into how human cells might combat aging and prolong lifespan, according to the report.With an evolutionary history of over 520 million years, these flatworms can regrow entire heads or tails when cut, making them ideal subjects for tissue regeneration research and a popular choice in biological studies.The space station has previously hosted zebrafish and fruit flies as model organisms for in-orbit biological experiments.In April 2024, Shenzhou 18 carried four zebrafish and four grams of goldfish algae to the Chinese…
Obama